The findings on orforglipron come from ATTAIN-MAINTAIN, a first-of-its-kind phase 3 trial conducted by the GLP-1 drugmaker Eli Lilly, which manufactures Zepbound and is developing the new oral medication
These include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), tirzepatide (Mounjaro, Zepbounda dual GIP/GLP-1 agonist), exenatide (Byetta, Bydureon BCise), and lixisenatide (Adlyxin)
17 pounds in 60 days 1 Low-dose GLP-1 designed to reduce observable side effects All-inclusive pricing: clinical care and medication Full access to Nooms program , focused on behavioral change and psychology for lasting results
Recycling of spent shiitake substrate for production of the oyster mushroom, Pleurotus sajor-caju
Unlike some GLP-1 medications, Calocurb is reported to have no ongoing side effects